MY169331A - Vaccine against rsv - Google Patents

Vaccine against rsv

Info

Publication number
MY169331A
MY169331A MYPI2014702664A MYPI2014702664A MY169331A MY 169331 A MY169331 A MY 169331A MY PI2014702664 A MYPI2014702664 A MY PI2014702664A MY PI2014702664 A MYPI2014702664 A MY PI2014702664A MY 169331 A MY169331 A MY 169331A
Authority
MY
Malaysia
Prior art keywords
vaccine against
rsv
against rsv
serotype
protein
Prior art date
Application number
MYPI2014702664A
Other languages
English (en)
Inventor
Katarina Radosevic
Jerome H H V Custers
Jort Vellinga
Myra N Widjojoatmodjo
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MY169331A publication Critical patent/MY169331A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MYPI2014702664A 2012-03-22 2013-03-21 Vaccine against rsv MY169331A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261614429P 2012-03-22 2012-03-22
EP12160682 2012-03-22

Publications (1)

Publication Number Publication Date
MY169331A true MY169331A (en) 2019-03-21

Family

ID=49221877

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI2014702664A MY169331A (en) 2012-03-22 2013-03-21 Vaccine against rsv
MYPI2014702662A MY169352A (en) 2012-03-22 2013-03-21 Vaccine against rsv

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI2014702662A MY169352A (en) 2012-03-22 2013-03-21 Vaccine against rsv

Country Status (15)

Country Link
EP (2) EP2827894B1 (enExample)
JP (2) JP5805908B2 (enExample)
KR (2) KR102023791B1 (enExample)
CN (2) CN104334188B (enExample)
AP (2) AP2014007993A0 (enExample)
AR (2) AR090469A1 (enExample)
AU (2) AU2013237424B2 (enExample)
BR (1) BR112014023196B1 (enExample)
CA (2) CA2867955C (enExample)
EA (2) EA026620B1 (enExample)
MY (2) MY169331A (enExample)
NZ (2) NZ630649A (enExample)
SG (2) SG11201405803PA (enExample)
TW (2) TWI640534B (enExample)
WO (2) WO2013139911A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3842068A1 (en) 2012-07-05 2021-06-30 GlaxoSmithKline Biologicals S.A. Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
WO2014168821A1 (en) * 2013-04-08 2014-10-16 Medimmune, Llc Vaccine composition and method of use
AU2014259474B2 (en) 2013-04-25 2018-09-13 Janssen Vaccines & Prevention B.V. Stabilized soluble prefusion RSV F polypeptides
EP3010931B1 (en) 2013-06-17 2018-06-13 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
JP6664338B2 (ja) 2014-06-13 2020-03-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組合せ物
US10100372B2 (en) 2014-06-18 2018-10-16 Georgia State University Research Foundation, Inc. Recombinant RSV reporter virus
WO2016144675A1 (en) * 2015-03-06 2016-09-15 Medimmune, Llc Vaccine dose and use thereof
SI3283634T1 (sl) 2015-04-14 2019-08-30 Janssen Vaccines & Prevention B.V. Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem
CN108025058B (zh) * 2015-06-12 2022-12-16 葛兰素史密丝克莱恩生物有限公司 腺病毒多核苷酸和多肽
CA2991540A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion respiratory syncytial sirus polypeptides
AU2016289492B2 (en) 2015-07-07 2022-08-11 Janssen Vaccines & Prevention B.V. Vaccine against RSV
KR102136678B1 (ko) 2015-12-23 2020-07-22 화이자 인코포레이티드 Rsv f 단백질 돌연변이체
PT3439672T (pt) 2016-04-05 2021-02-24 Janssen Vaccines & Prevention Bv Proteína f do rsv pré-fusão solúvel e estabilizada para uso na profilaxia de infeção por rsv
WO2017174564A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
AU2017264562B2 (en) 2016-05-12 2023-03-09 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
WO2017207480A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
AU2017283118B2 (en) 2016-06-20 2019-02-07 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
SG11201906271QA (en) 2017-02-09 2019-08-27 Janssen Vaccines & Prevention Bv Potent and short promoter for expression of heterologous genes
EP3624844A1 (en) * 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2018210871A1 (en) * 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2019053109A1 (en) * 2017-09-15 2019-03-21 Janssen Vaccines & Prevention B.V. METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV
PH12021550974A1 (en) 2018-11-13 2022-05-02 Janssen Vaccines & Prevention Bv Stablized pre-fusion rsv f proteins
KR20220008875A (ko) * 2019-05-15 2022-01-21 얀센 백신스 앤드 프리벤션 비.브이. 계절성 인플루엔자 백신과 아데노바이러스 기반 호흡기 세포융합 바이러스 백신의 공동투여
JP2022532742A (ja) * 2019-05-15 2022-07-19 ヤンセン ファッシンズ アンド プリベンション ベーフェー アデノウイルスベースのワクチンによる呼吸器合胞体ウイルス感染の予防的処置
AU2021270777A1 (en) 2020-05-12 2022-11-10 Janssen Vaccines & Prevention B.V. Administration of homologous adenoviral vectors
MX2022002609A (es) * 2020-08-22 2022-06-08 Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte Vector de expresion para el desarrollo de un agente inmunobiologico para inducir inmunidad especifica contra el virus de sindrome respiratorio agudo grave sars-cov-2 (variantes).
EA037297B9 (ru) * 2020-08-22 2021-11-24 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Фармацевтическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома sars-cov-2 (варианты)
RU2731356C9 (ru) * 2020-08-22 2021-10-05 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Экспрессионный вектор для создания иммунобиологического средства для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
RU2731342C9 (ru) * 2020-08-22 2021-10-05 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Фармацевтическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
CN112226444B (zh) * 2020-08-25 2022-11-04 北京交通大学 呼吸道合胞病毒全长融合前融合糖蛋白核苷酸序列、重组腺病毒载体及其应用产品
CN112220921B (zh) * 2020-08-25 2022-08-16 北京交通大学 一种针对呼吸道合胞病毒感染的组合疫苗
WO2022215436A1 (ja) * 2021-04-05 2022-10-13 株式会社クボタ 管理機制御システム
CA3252878A1 (en) * 2022-05-10 2025-07-07 Cansino Biologics Inc. Adenoviral vector vaccine against respiratory syncytial virus, its preparation method and use
CN116003536A (zh) * 2022-09-23 2023-04-25 暨南大学 呼吸道合胞病毒融合前f蛋白突变体及其应用
WO2024093554A1 (zh) * 2022-11-04 2024-05-10 北京康乐卫士生物技术股份有限公司 针对rsv的重组亚单位疫苗及其应用
CN117050149B (zh) * 2023-05-19 2025-12-12 珠海丽凡达生物技术有限公司 包含人呼吸道合胞病毒抗原的免疫组合物及其制备方法和应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2177085C (en) 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
JP2000514290A (ja) 1996-07-01 2000-10-31 ローヌ―プーラン・ロレ・エス・アー 組換えアデノウイルスの製造方法
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
KR100503701B1 (ko) 1996-11-20 2005-07-26 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
WO1998039411A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
WO1999041416A2 (en) 1998-02-17 1999-08-19 Schering Corporation Compositions comprising viruses and methods for concentrating virus preparations
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
EP1133316B1 (en) 1998-11-16 2009-01-21 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
DK1550722T3 (da) 1999-05-17 2007-10-08 Crucell Holland Bv Rekombinant human adenovirus serotype 35
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
EP1263461A4 (en) 2000-03-07 2009-08-12 Merck & Co Inc ADENOVIRUS FORMULATIONS
WO2003049763A1 (en) 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for the preservation of viruses
EP1465664A1 (en) 2002-01-18 2004-10-13 Schering Aktiengesellschaft Stabilized formulations of adenovirus
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
WO2004001032A2 (en) 2002-04-25 2003-12-31 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
BR0308783A (pt) 2002-04-25 2005-01-04 Crucell Holland Bv Vetor de adenovìrus recombinante, método para produzir um vetor de adenovìrus recombinante, composição farmacêutica, método para tratar um corpo humano, e, kit de partes
WO2003097797A2 (en) 2002-05-14 2003-11-27 Merck & Co., Inc. Methods of adenovirus purification
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
AU2003268210A1 (en) 2002-08-28 2004-03-19 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
HRP20130616T1 (en) * 2003-10-02 2013-08-31 Crucell Holland B.V. Packaging cells for recombinant adenovirus
ES2329607T3 (es) 2004-02-23 2009-11-27 Crucell Holland B.V. Metodos de purificacion de virus.
DE602005025340D1 (de) * 2004-05-26 2011-01-27 Bayer Schering Pharma Ag Chimäre adenoviren zur verwendung in der krebsbehandlung
JP4843613B2 (ja) * 2004-10-13 2011-12-21 クルセル ホランド ベー ヴェー 改良されたアデノウイルスベクターおよびその使用方法
WO2006086284A2 (en) * 2005-02-11 2006-08-17 Merck & Co., Inc. Adenovirus serotype 26 vectors, nucleic acid and viruses produced thereby
CA2602944C (en) 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
WO2007110409A1 (en) 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
DE102006060799A1 (de) 2006-12-21 2008-06-26 RUHR-UNIVERSITäT BOCHUM RSV F-Protein und seine Verwendung
CN101012463A (zh) * 2007-01-19 2007-08-08 安徽医科大学 HDAd/F载体及制备方法和用途
WO2009117134A2 (en) 2008-03-21 2009-09-24 National Institutes Of Health Aerosolized genetic vaccines and methods of use
DK2350268T3 (en) 2008-11-03 2015-03-23 Crucell Holland Bv PROCEDURE FOR PRODUCING ADENOVIRUS VECTORS
US9095546B2 (en) 2009-07-20 2015-08-04 National Health Research Institutes Human respiratory syncytial virus (RSV) vaccine
CN102791852B (zh) 2009-10-15 2014-05-07 克鲁塞尔荷兰公司 纯化腺病毒颗粒的方法
KR101805938B1 (ko) 2009-10-15 2018-01-10 얀센 백신스 앤드 프리벤션 비.브이. 고밀도 세포 배양액에서 아데노바이러스의 정제 방법
CN102753582A (zh) * 2009-11-03 2012-10-24 莱戈赛特医药股份有限公司 嵌合RSV-F多肽、和慢病毒或α-反转录病毒GAG基VLP
KR101820980B1 (ko) 2010-02-15 2018-01-22 얀센 백신스 앤드 프리벤션 비.브이. Ａｄ 26 아데노바이러스 벡터를 제조하는 방법
WO2012021730A2 (en) * 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine

Also Published As

Publication number Publication date
CN104334188A (zh) 2015-02-04
TWI624545B (zh) 2018-05-21
AU2013237424B2 (en) 2017-07-06
WO2013139916A1 (en) 2013-09-26
EP2827895B1 (en) 2017-08-09
BR112014023196B1 (pt) 2021-09-08
SG11201405804YA (en) 2014-10-30
AU2013237424A1 (en) 2014-10-16
CN105431169B (zh) 2019-04-02
AU2013237429B2 (en) 2015-07-23
TWI640534B (zh) 2018-11-11
AR090469A1 (es) 2014-11-12
WO2013139911A1 (en) 2013-09-26
EP2827895A1 (en) 2015-01-28
CN105431169A (zh) 2016-03-23
NZ630753A (en) 2016-12-23
CA2867955C (en) 2023-02-07
TW201343669A (zh) 2013-11-01
EA026620B1 (ru) 2017-04-28
EA026504B1 (ru) 2017-04-28
EP2827894A1 (en) 2015-01-28
CA2867950C (en) 2023-02-21
JP5805908B2 (ja) 2015-11-10
CN104334188B (zh) 2016-08-24
EA201491754A1 (ru) 2014-12-30
CA2867955A1 (en) 2013-09-26
AU2013237429A1 (en) 2014-10-09
AP2014007993A0 (en) 2014-10-31
BR112014023196A2 (enExample) 2017-06-20
JP2015512380A (ja) 2015-04-27
EA201491752A1 (ru) 2015-02-27
JP2015519295A (ja) 2015-07-09
CA2867950A1 (en) 2013-09-26
AP2014007994A0 (en) 2014-10-31
KR20140138765A (ko) 2014-12-04
SG11201405803PA (en) 2014-11-27
MY169352A (en) 2019-03-25
EP2827894B1 (en) 2017-05-17
NZ630649A (en) 2016-12-23
TW201341531A (zh) 2013-10-16
KR20140138769A (ko) 2014-12-04
JP5845376B2 (ja) 2016-01-20
AR090470A1 (es) 2014-11-12
KR102050616B1 (ko) 2019-12-03
KR102023791B1 (ko) 2019-09-23

Similar Documents

Publication Publication Date Title
MY169331A (en) Vaccine against rsv
CY1121600T1 (el) Σταθεροποιημενα διαλυτα πολυπεπτιδια rsv f προσυντηξης
PH12018500856A1 (en) Respiratory syncytial virus vaccine
CY1117673T1 (el) Ανασυνδυασμενα αντιγονα rsv
GEP20217260B (en) Antibody neutralizing human respiratory syncytial virus
WO2012024621A3 (en) Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus hemagglutinin
WO2018089851A3 (en) Influenza vaccine
CL2015003655A1 (es) Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados
EP4501318A3 (en) Nucleic acid vaccines
EA201890527A1 (ru) Терапевтические вакцины против hpv18
WO2016086088A3 (en) Wound healing through sirt1 overexpression
IL236744A0 (en) A modified recombinant vaccinia ankara virus respiratory syncytial virus assembly
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2012021730A3 (en) Respiratory syncytial virus (rsv) vaccine
WO2013006569A3 (en) Herpes virus vaccine and methods of use
BR112012008338A2 (pt) combinação de vacinas contra doenças do trato respiratório.
ZA201500606B (en) Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
WO2006115843A3 (en) Nipah virus vaccines
WO2011156641A3 (en) Microneedle arrays for active agent delivery
WO2013152274A8 (en) Epitope- scaffold immunogens against respiratory syncytial virus (rsv)
WO2015041924A8 (en) Recombinant respiratory syncytial virus (rsv) and vaccines
PH12014502086A1 (en) Vaccine against rsv
HK40016413A (en) Respiratory virus nucleic acid vaccines
TH1101001042B (th) รีคอมบิเเนนท์เวคเตอร์ซึ่งประกอบด้วยยีนที่เข้ารหัสฮิวเเมน กลูโคไคเนส
MX2012006516A (es) Composicion adyuvante de vacuna a base de acido ursolico.